NCT05148546 - Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 28, 2022

Primary Completion Date

April 22, 2025

Study Completion Date

April 30, 2029

Conditions

Renal Cell Carcinoma

Interventions

DRUG

Neoadjuvant nivolumab

Patients will receive 2 cycles of nivolumab 360mg (arm A and C) or 3mg/kg (arm B) every 3 weeks followed by a nephrectomy.

DRUG

Neoadjuvant ipilimumab

Patients will receive 2 cycles of ipilimumab 1mg/kg every 3 weeks followed by a nephrectomy.

DRUG

Neoadjuvant relatlimab

Patients will receive 2 cycles of relatlimab 360mg every 3 weeks followed by a nephrectomy.

Trial Locations (2)

Netherlands Cancer Institute, Amsterdam

Royal Free London NHS Foundation Trust, London